Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer

Author(s): Martin Swinton, MBBChir1,2; Neethu Billy Graham Mariam, MBChB1; Jean Ling Tan, MBChB2; Katherine Murphy, MBChB3; Thiraviyam Elumalai, MD4; Manjusha Soni, MBBS, MD5; Alexandra Ferrera, MBChB1; Charlotte Richardson, MBChB5; Richard Walshaw, MBChB, PhD3; Hitesh Mistry, PhD2; Vijay Ramani, MBBS1; Yeepei Song, MBBCh, MD1; Alison Birtle, MBBS, MD6; Ann Henry, MBChB, MD5; Joachim Chan, MBBS, MD3; Peter Hoskin, MD2; and Ananya Choudhury, MA, PhD1,2
Source: DOI: 10.1200/JCO.23.00725 Journal of Clinical Oncology 41, no. 27 (September 20, 2023) 4406-4415.

Dr. Anjan Patel's Thoughts

The poor OS of 1.5 years in node-positive patients is striking in this retrospective review of 287 patients treated with definitive intent. The OS was not different between those treated with TURBT + chemoradiation vs. chemotherapy + radical cystectomy, suggesting that surgery may not be superior to multi-modal therapy and QOL may be superior in a non-operative approach.

PURPOSE

Bladder-sparing trimodal therapy (TMT) is an alternative to radical cystectomy (RC) according to international guidelines. However, there are limited data to guide management of nonmetastatic clinically node-positive bladder cancer (cN+ M0 BCa). We performed a multicenter retrospective analysis of survival outcomes in node-positive patients to inform practice.

METHODS

Data from patients diagnosed with cN+ M0 BCa were collected from participating UK Oncology centers offering both TMT and RC. Overall survival (OS) and progression-free survival (PFS) outcomes were collected with details of treatment and clinical factors.

RESULTS

A total of 287 patients with cN+ M0 BCa were included in the survival analysis. Median OS across all patients was 1.55 years (95% CI, 1.35 to 1.82 years). Receiving radical treatments was associated with improved OS (hazard ratio [HR], 0.32; 95% CI, 0.23 to 0.44; P < .001) compared with receiving palliative treatment. Radically treated patients (n = 163) received RC (n = 76) or radical dose radiotherapy (RT, n = 87); choice of radical treatment showed no association with OS (HR, 0.94; 95% CI, 0.63 to 1.41; P = .76) or PFS (HR, 0.74; 95% CI, 0.50 to 1.08; P = .12) on multivariable analysis.

CONCLUSION

Patient cohorts with cN+ M0 BCa had equivalent survival outcomes whether treated with surgery or radical RT. Given the known morbidities of RC—in a patient group with poor survival—this study confirms that bladder-sparing TMT treatment should be a treatment option available to all patients with cN+ M0 BCa.

Author Affiliations

1Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; 2University of Manchester, Manchester, United Kingdom; 3Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom; 4Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; 5Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; 6Rosemere Cancer Centre, Royal Preston Hospital, Preston, United Kingdom

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis

Retrospective review showing equivocal outcomes in cT2-T4N0 patients treated with radical cystectomy vs TURBT + chemoradiation. There were similar rates of neoadjuvant chemotherapy being given in both groups. Based on prospective data, the SOC remains cisplatin-based neoadjuvant chemo followed by radical cystectomy; however, trimodality therapy may not have worse outcomes, and it would be great to see a prospective head-to-head study.

Read More »